Labopharm Inc (DDS.TO) Buy, Sell or Hold

Labopharm Inc (DDS.TO)

0.00

-0.00 (0.00%)

2 watching

HOLD

Broke through the 200-day moving average at about $1.50. Looks like the momentum may start to peter out but there is some pretty good support around $1.40. If her broke that, you should Sell.

DON'T BUY

Has disappointed everyone for a long time. Didn't get approval on their product. Stock has been decimated. Thinks the worst is over, but it will be a long recovery. He was actually Short the stock for a while. If you own, Hold and see what they do, but don't be a buyer.

SELL

Has been a major disappointment. Guided that approvals would be fairly easy to receive, which didn't happen. Trials have been okay, not all that inclusive, so there is a lot of uncertainty.

BUY

Has been doing fairly well recently because they had their European and Canadian approval for their painkiller. Once they get the US of the way, it should be back over the $7 mark.

BUY

It is a small stock. Believes it will be a winner.

WATCH

Entering into a licensing/distribution agreement with Purdue Pharma in the US. Did a disatrous financing last year and the stock sold off. This deal was a rabbit pulled out of a hat. The stock will probably flatline for a bit after this deal. Best to see quarter after quarter how revenues kick in.

DON'T BUY

Received approval in France for its drug tramadol. Has stubbed its toes many times with investors. Large outstanding stock holding (40 Million?) could come out and flood the market.

DON'T BUY

Drug companies in general scare value investors. Drugs they produce might injure or kill people. Also there's a history of companies suing each other because of infringement on property rights which can tie up a small company like this. Although they got French approval, FDA could be a whole different matter.

WATCH

Management is at its risk. If they start in Europe, the stock will improve. Therefore, be cautious.

DON'T BUY

Did an issue and it was a disaster. Hasn't even come close to where the issue was priced at. Behind schedule as compared to their competitors.

DON'T BUY

Still suffering from a plethora of disappointments from late 2001 and 2002. Will have a challenge moving up from where it is. Prefers others.

DON'T BUY

Volatile. Too few projects on the go. Risky.

DON'T BUY

Interesting technology. Future is unclear. Risky.

PAST TOP PICK

(Was a top pick on Dec 18 down 46%) Still likes. Got hit with the pull out of Aventis, but should be able to get new deals over the next 6 months. Don't buy until they do strike a deal.

DON'T BUY

Speculative and risky. In a competitive sector.

Showing 1 to 15 of 28 entries

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Labopharm Inc (DDS.TO) Frequently Asked Questions

What is Labopharm Inc stock symbol?

Labopharm Inc is a OTC stock, trading under the symbol DDS.TO (previously DDS-T on Stockchase) on the undefined (undefined). It is usually referred to as or DDS.TO

Is Labopharm Inc a buy or a sell?

In the last year, no analyst issued a Buy, Sell, or Hold rating on DDS.TO (previously DDS-T on Stockchase) on Stockchase. Read the latest expert commentary for Labopharm Inc.

Is Labopharm Inc a good investment or a top pick?

Labopharm Inc was recommended as a Top Pick by Jonathen Wellum, B. Comm, B. Sc on 2002-03-15. Read the latest stock experts ratings for Labopharm Inc.

Why is Labopharm Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Labopharm Inc.

Is Labopharm Inc worth watching?

Labopharm Inc is covered by Stockchase experts and is worth watching.

Most Recent Experts

Stockchase Insights

5i Research

Brian Acker, CA

Acker Finley Inc.

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

David Burrows

Barometer Capital Management

Jim Cramer - Mad Money

CNBC

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Labopharm Inc (DDS.TO)